News

Standing up in public for a broader conception of value in healthcare.

17-24 of 59 News

viewpoint 4/03/17

On the Health Affairs Blog: Blumenthal, Linthicum and Kamal-Bahl Address Outcomes-Based Pricing Agreements Daniel Blumenthal, Mark Linthicum, and Sachin Kamal-Bahl outline the key challenges and strategies surrounding the establishment of outcomes-based pricing agreements. READ MORE

viewpoint 3/31/17

On the Health Affairs Blog: Horn and Dickson Offer Proposals to Modernize and Strengthen Drug Pricing Regulations Tim Horn and Sean Dickson offer four proposals for strengthening existing regulations to reduce drug prices while incentivizing scientific ingenuity and discovery. READ MORE

viewpoint 3/23/17

On the Health Affairs Blog: Avorn Assesses the Landscape for Prescription Drug Regulation, Promotion, and Advocacy Jerry Avorn provides a summary of the year's developments in health law, focusing on the 21st Century Cures Act, the appointment of a new FDA Commissioner, and "academic detailing." READ MORE

viewpoint 3/21/17

On the Health Affairs Blog: Bronstein and Co-Authors Champion The OPEN Act as a Pathway to Accelerated Drug Development Max Bronstein and co-authors discuss the OPEN ACT and the current drug development landscape, urging the passing into law of this new legislation. READ MORE

viewpoint 3/20/17

On the Health Affairs Blog: Bohrer Discusses Accelerated Approval for New Drugs, and Suggests a Conditional Approval Option Robert Bohrer discusses the balancing act between drug pricing and the approvals process, suggesting a new "conditional approval" approach may be the best compromise. READ MORE

viewpoint 3/14/17

On the Health Affairs Blog: ​Rosenberg-Wohl and Coauthors Report on "Wisdom Study" CED Model Sarah Rosenberg-Wohl and coauthors discuss the potential of private insurer funding for CER through "Coverage with Evidence Development", using The Wisdom Study as a real-world case study. READ MORE

viewpoint 3/10/17

On the Health Affairs Blog: Claire Laporte Explains the "Patent Dance" for Biosimilars, and the Importance of Trade Secrets Claire Leporte breaks down the pathway provided by the new aBLA patent process for manufacturers of biosimilars, illustrating what's at stake and how it impacts intellectual property laws and the preservation of trade secrets. READ MORE

viewpoint 3/07/17

On the Health Affairs Blog: Bach, Helms and Yu Examine Links Between R&D Costs and Drug Prices Peter Bach, Zachary Helms, and Nancy Yu leverage public data to estimate both the premiums that companies earn and the amount they spend on research, challenging pharmaceutical companies' claims regarding R&D spending. READ MORE